Grbic, J.T., Black, D.M., Lyles, K.W., Reid, D.M., Orwoll, E., McClung, M., et al. (2010) The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid: Data from the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Clinical Trials Program. The Journal of the American Dental Association, 141, 1365-1370.
https://doi.org/10.14219/jada.archive.2010.0082

has been cited by the following article:

• TITLE: Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis

  AUTHORS: IsraaIsraa Ahmed Radwan, Nahed Sedky Korany, Bassant Adel Ezzat

  KEYWORDS: Bisphosphonates, Alendronate, Zoledronate, Postmenopausal Osteoporosis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.7 No.5, May 10, 2018

  ABSTRACT: Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We review here two of the commonly used bisphosphonates zoledronate and alendronate.